Corrigendum: Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Annals of Oncology (2018) 29 (iv238–iv255) DOI: 10.1093/annonc/mdy308)

Ann Oncol 2018; 29: iv238-iv255 (doi:10.1093/annonc/mdy308) The following corrections are made: Under authorship: The author name: J. Llovet is replaced with: J. M. Llovet The author B. Daniele's affiliation: Direttore Dipartimento di Oncologia e U.O.C. Oncologia Medica A.O., Benevento, Italy is replaced with: Dipartimento di Oncologia, A.O. G. Rummo, Benevento, Italy In "Table 4. BCLC staging and treatment options according to level of evidence and approval status, BCLC stage C" Nivolumab (second-line) [I, B] Is replaced with: Nivolumab (second-line) [III, B] Pembrolizumab (second-line) [I, B] Is replaced with: Pembrolizumab (second-line) [III, B] In "Figure 1. HCC treatment options depending on BCLC stage" Under BCLC O-A: On the left side, the arrow between the treatments in the top and middle row are removed, and new footnote is added for each treatment in the second box: SBRTc Brachytherapyc SIRTc [III, C] cNon-standard, alternative treatment. On the right side, the two treatments are combined into one box: Ablation [III, A]a TACE [I, B] Under BCLC B: SIRT [III, C] is moved to a new position in the figure and a new footnote is added: SIRT [III, C]c cNon-standard, alternative treatment. Under BCLC C: The following changes apply as shown in the updated version below. Sorafeniba Is replaced with: Sorafeniba [I, A] Nivolumabb [I, B] Is replaced with: Nivolumabb [III, C] Regorafeniba Cabozantinibb Ramucirumabb [I, A] Nivolumabb Pembrolizumabb [III, B] Is replaced with: Regorafeniba [I, A] Cabozantinibb [I, A] Ramucirumabb [I, A] Nivolumabb[III, B] Pembrolizumabb [III, B]. (Figure Presented).